BIOMAT Database Logo BIOMAT Database Logo

Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer. 2010

Masakazu Sugaya, and Hidetaka Uramoto, and Akihiko Uchiyama, and Akira Nagashima, and Ryoichi Nakanishi, and Hisanobu Sakata, and Kozo Nakanishi, and Takeshi Hanagiri, and Kosei Yasumoto
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan.

BACKGROUND Adjuvant chemotherapy improves the prognosis of patients with non-small cell lung cancer (NSCLC) after a complete resection despite unacceptable toxicity and low compliance. METHODS A total of 67 patients were enrolled in a multi-institutional study. The patients received chemotherapy with carboplatin (CBDCA) area under the curve of 3 and paclitaxel (PTX) 90 mg/m(2) every 2 weeks for six cycles after surgery. RESULTS Fifty patients (74.6%) completed all cycles of therapy. The presence of grade 3 and 4 toxicities of neutropenia were 13.4, and 3.0%, respectively. Non-haematological adverse effects were infrequent and no treatment-related death was registered. The estimated disease-free survival and overall survival at 2 years were 89.0% and 88.8%, respectively. CONCLUSIONS A bi-weekly schedule of CBDCA and PTX as adjuvant chemotherapy showed an acceptable toxicity and favourable feasibility in Japanese NSCLC patients after complete tumor resection. Consequently, it is desirable to validate this regimen in a future randomized clinical trial.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Masakazu Sugaya, and Hidetaka Uramoto, and Akihiko Uchiyama, and Akira Nagashima, and Ryoichi Nakanishi, and Hisanobu Sakata, and Kozo Nakanishi, and Takeshi Hanagiri, and Kosei Yasumoto
A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
November 2010, Anticancer research,
Masakazu Sugaya, and Hidetaka Uramoto, and Akihiko Uchiyama, and Akira Nagashima, and Ryoichi Nakanishi, and Hisanobu Sakata, and Kozo Nakanishi, and Takeshi Hanagiri, and Kosei Yasumoto
Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.
March 2020, Lung cancer (Amsterdam, Netherlands),
Masakazu Sugaya, and Hidetaka Uramoto, and Akihiko Uchiyama, and Akira Nagashima, and Ryoichi Nakanishi, and Hisanobu Sakata, and Kozo Nakanishi, and Takeshi Hanagiri, and Kosei Yasumoto
S-1 vs. paclitaxel plus carboplatin as adjuvant chemotherapy for completely resected stage II/IIIA non-small-cell lung cancer.
January 2018, Molecular and clinical oncology,
Masakazu Sugaya, and Hidetaka Uramoto, and Akihiko Uchiyama, and Akira Nagashima, and Ryoichi Nakanishi, and Hisanobu Sakata, and Kozo Nakanishi, and Takeshi Hanagiri, and Kosei Yasumoto
Feasibility study of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected non-small-cell lung cancer: FAST-nab.
August 2017, Anti-cancer drugs,
Masakazu Sugaya, and Hidetaka Uramoto, and Akihiko Uchiyama, and Akira Nagashima, and Ryoichi Nakanishi, and Hisanobu Sakata, and Kozo Nakanishi, and Takeshi Hanagiri, and Kosei Yasumoto
Feasibility of postoperative adjuvant chemotherapy using carboplatin plus S-1 in completely resected non-small cell lung cancer patients.
October 2019, Journal of chemotherapy (Florence, Italy),
Masakazu Sugaya, and Hidetaka Uramoto, and Akihiko Uchiyama, and Akira Nagashima, and Ryoichi Nakanishi, and Hisanobu Sakata, and Kozo Nakanishi, and Takeshi Hanagiri, and Kosei Yasumoto
Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients.
January 2005, Anticancer research,
Masakazu Sugaya, and Hidetaka Uramoto, and Akihiko Uchiyama, and Akira Nagashima, and Ryoichi Nakanishi, and Hisanobu Sakata, and Kozo Nakanishi, and Takeshi Hanagiri, and Kosei Yasumoto
Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.
October 2014, Translational lung cancer research,
Masakazu Sugaya, and Hidetaka Uramoto, and Akihiko Uchiyama, and Akira Nagashima, and Ryoichi Nakanishi, and Hisanobu Sakata, and Kozo Nakanishi, and Takeshi Hanagiri, and Kosei Yasumoto
[A phase II study of gemcitabine and carboplatin bi-weekly combination chemotherapy for complete resected non-small-cell lung cancer patients].
September 2010, Kyobu geka. The Japanese journal of thoracic surgery,
Masakazu Sugaya, and Hidetaka Uramoto, and Akihiko Uchiyama, and Akira Nagashima, and Ryoichi Nakanishi, and Hisanobu Sakata, and Kozo Nakanishi, and Takeshi Hanagiri, and Kosei Yasumoto
Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.
July 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Masakazu Sugaya, and Hidetaka Uramoto, and Akihiko Uchiyama, and Akira Nagashima, and Ryoichi Nakanishi, and Hisanobu Sakata, and Kozo Nakanishi, and Takeshi Hanagiri, and Kosei Yasumoto
A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer.
June 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Copied contents to your clipboard!